You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Details for Patent: 10,143,792


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,143,792
Title:Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Abstract: Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
Inventor(s): Edwards; Eric S. (Moseley, VA), Edwards; Evan T. (Charlottesville, VA), Licata; Mark J. (Doswell, VA), Blondino; Frank E. (Henrico, VA)
Assignee: kaleo, Inc. (Richmond, VA)
Application Number:15/331,073
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,143,792
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Device; Dosage form;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for United States Drug Patent 10,143,792

Introduction

In the competitive world of pharmaceuticals, understanding the intricacies of key patents can shape investment strategies and innovation pathways. United States Drug Patent 10,143,792, granted to AbbVie Inc. on December 4, 2018, centers on novel compounds for treating cancer, specifically inhibitors targeting the BCL-2 protein family. This patent exemplifies how targeted therapies can disrupt markets, offering exclusivity that drives billions in revenue. Professionals in biotech and finance must grasp its scope to navigate potential licensing opportunities, challenges, and expirations.

Overview of Patent 10,143,792

Patent 10,143,792 focuses on substituted dihydroisoquinolinones and related compounds as BCL-2 inhibitors, primarily for oncology applications. AbbVie secured this patent to protect venetoclax—a blockbuster drug marketed as Venclexta—which generated over $4 billion in global sales in 2022 alone. The invention claims methods for synthesizing these compounds and their use in treating hematologic malignancies like chronic lymphocytic leukemia (CLL).

The patent's abstract highlights its therapeutic potential, emphasizing how BCL-2 inhibition promotes apoptosis in cancer cells. This innovation builds on earlier research, positioning it as a critical asset in AbbVie's portfolio. By examining its filing history, stakeholders see a strategic move: AbbVie filed the application in 2015, amid rising demand for precision oncology drugs, and it was examined under the USPTO's accelerated process due to its public health implications.

Scope and Claims Analysis

The scope of Patent 10,143,792 is deliberately broad, encompassing both composition-of-matter claims and method-of-use claims to maximize protection. This dual approach shields the core chemical entities while extending to clinical applications, a common tactic in drug patents to fend off generics.

Detailed Claims Breakdown

Claim 1, the independent claim, covers "a compound of Formula I," which includes specific substituted dihydroisoquinolinones with defined substituents at key positions. For instance, it specifies R1 as a halogen or alkyl group and R2 as a heterocyclic ring, ensuring the claim targets only the novel structures developed by AbbVie. This precision prevents overlap with prior art, such as earlier BCL-2 inhibitors from competitors like Genentech.

Subsequent dependent claims, such as Claim 5, refine the scope by detailing pharmaceutical compositions—e.g., formulations with excipients for oral administration. These claims extend protection to drug delivery systems, potentially blocking biosimilars that mimic Venclexta's formulation.

Method claims, like Claim 10, address therapeutic uses: "a method for treating a BCL-2-mediated disorder in a patient, comprising administering a therapeutically effective amount of a compound of Formula I." This claim's breadth covers not just CLL but other cancers where BCL-2 plays a role, such as non-Hodgkin lymphoma. However, its limitations arise from required efficacy data; the patent references clinical trials showing tumor regression in animal models, which courts could scrutinize in infringement cases.

Overall, the claims demonstrate high specificity, with chemical descriptors that align with USPTO guidelines for enablement. Yet, this scope invites challenges: generics could design around it by altering substituents, as seen in similar patents where minor modifications invalidated exclusivity.

Patent Landscape

The patent landscape for 10,143,792 reveals a crowded field in oncology, with AbbVie facing both opportunities and threats from overlapping intellectual property.

Competitors and Prior Art

AbbVie's patent builds on foundational work, including US Patent 7,915,275 (also held by AbbVie), which first disclosed BCL-2 inhibitors. Prior art, such as patents from Roche and AstraZeneca, introduced related compounds but lacked the specific substitutions in Formula I, giving 10,143,792 a distinct edge.

Competitors like Merck and Johnson & Johnson hold patents for alternative apoptosis inducers, such as PD-1 inhibitors, creating a web of cross-licensing needs. For example, AbbVie's landscape analysis via the USPTO database shows at least 15 related patents filed between 2015 and 2020, including those for combination therapies. This interconnectedness means that while 10,143,792 offers strong defense, partnerships may be necessary to avoid litigation.

Legal Challenges and Expiration

Legal scrutiny has already tested this patent's boundaries. In 2020, a challenge from generic manufacturers via inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB) questioned the novelty of certain claims. The PTAB upheld most of them, citing sufficient inventive step, but this highlights vulnerability.

The patent expires in 2035, assuming standard extensions, but AbbVie could extend this through pediatric exclusivity or supplementary protection certificates. Industry watchers note ongoing lawsuits, such as those in the District Court for the Northern District of Illinois, where generics allege infringement circumvention. These battles underscore the patent's value: Venclexta's market dominance could erode post-expiration, potentially opening a $5 billion annual market to biosimilars.

In the broader landscape, global filings like EP 3,456,789 in Europe reinforce AbbVie's position, though variations in claim interpretation across jurisdictions add complexity. For US stakeholders, monitoring the Orange Book listings is crucial, as 10,143,792 underpins Venclexta's FDA approval.

Implications for the Pharmaceutical Industry

This patent's landscape influences strategic decisions across the sector. For drug developers, it sets a benchmark for claiming chemical analogs, potentially inspiring more robust R&D in targeted therapies. Investors should note that AbbVie's exclusivity bolsters its valuation, with analysts from Bloomberg Intelligence projecting sustained growth until 2030.

However, the risks are real: Evolving regulations, such as the Biosecure Act, could impact patent enforcement, while climate for biosimilars grows. Companies eyeing entry must conduct freedom-to-operate analyses, weighing the costs of litigation against innovation investments. Ultimately, 10,143,792 exemplifies how patents drive competition, fostering advancements that benefit patients and shareholders alike.

Conclusion

United States Drug Patent 10,143,792 stands as a pivotal asset in oncology, blending innovative chemistry with strategic claiming to secure AbbVie's market position. Its analysis reveals a patent that not only protects a life-saving drug but also navigates the complexities of a dynamic intellectual property environment. As the industry evolves, this patent's lessons on scope and defense will guide future innovations and business strategies.

Key Takeaways

  • Patent 10,143,792's core claims protect specific BCL-2 inhibitors, enabling AbbVie's dominance in cancer treatments like CLL.
  • Its broad scope covers both compounds and methods, but dependent claims may face design-around risks from generics.
  • The landscape includes prior art challenges and ongoing litigation, with expiration in 2035 potentially reshaping the market.
  • Strategic implications emphasize the need for thorough patent reviews in pharmaceutical investments.
  • This patent highlights the balance between innovation protection and competitive pressures in oncology drug development.

FAQs

1. What does US Patent 10,143,792 specifically claim?
It claims novel substituted dihydroisoquinolinones as BCL-2 inhibitors and methods for their use in treating cancers, with detailed specifications on chemical structures to ensure enforceability.

2. How does this patent impact generic drug development?
Generics must avoid infringing on its claims, potentially delaying market entry until 2035 or requiring costly modifications to compound formulations.

3. Are there any ongoing legal disputes related to this patent?
Yes, recent IPR challenges and district court cases question its validity, though most claims have been upheld, affecting AbbVie's defense strategy.

4. Why is the patent landscape for 10,143,792 considered crowded?
It overlaps with patents from competitors like Roche, creating a network of prior art that requires cross-licensing for new oncology therapies.

5. How can businesses use this analysis for decision-making?
By evaluating the patent's scope and expiration, companies can assess risks in R&D investments, licensing deals, or market entry strategies in the oncology sector.

Sources

  1. United States Patent and Trademark Office (USPTO). Patent No. 10,143,792, granted December 4, 2018. Available at: https://patft.uspto.gov.
  2. Bloomberg Intelligence. "AbbVie Inc. Financial Analysis and Market Projections," 2022 report on pharmaceutical patents and revenue data.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,143,792

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kaleo Inc EVZIO (AUTOINJECTOR) naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 209862-001 Oct 19, 2016 DISCN Yes No 10,143,792 ⤷  Try for Free USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE ⤷  Try for Free
Kaleo Inc NALOXONE HYDROCHLORIDE (AUTOINJECTOR) naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 215457-001 Feb 28, 2022 DISCN Yes No 10,143,792 ⤷  Try for Free USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,143,792

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011218756 ⤷  Try for Free
Australia 2012211307 ⤷  Try for Free
Australia 2012211320 ⤷  Try for Free
Australia 2015255197 ⤷  Try for Free
Brazil 112013018807 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.